The present invention discloses an sirna that inhibits K-RAS gene expression, and the precursor sequences and applications thereof. The K-RAS sirna and its precursor sequences provided by the present invention can efficiently inhibit the expression of the K-RAS gene, and in vivo experiments have shown that the K-RAS sirna has a certain inhibitory effect on tumours highly expressing K-RAS. The precursor of the sirna of the invention and its vector can form a stable sirna that functions in a host.
|
11. An sirna for inhibiting expression of a K-RAS gene, wherein the nucleotide sequence of the sense strand of the sirna is seq id NO: 263, and to which directly or indirectly a sequence a1 and/or A2 is attached, wherein a1 is UGCUG and A2 is CAGG or CAGGA.
1. A precursor sequence having a structure from the 5′ terminus to the 3′ terminus as shown in formula I:
##STR00005##
wherein, B1 is a first ribonucleic acid sequence comprising a K-RAS sirna sense strand sequence;
B2 is a sequence substantially or completely complementary to B1, and B2 is not complementary to C; wherein substantially complementary means there are 2-8 non-complementary bases between B2 and B1;
C is a stem-loop structure sequence; and
a1 is UGCUG; and/or A2 is CAGG or CAGGA;
wherein the nucleotide sequence of the K-RAS sirna sense strand is selected from the following sequences as shown in the sequence listing: seq id NO: 263;
and the precursor sequence can be processed in a host to form the K-RAS sirna.
2. The precursor sequence of
5. An expression vector, comprising the precursor sequence of
6. A pharmaceutical composition, comprising
(a) an expression vector for expression of an sirna that inhibits K-RAS gene expression; and
(b) a pharmaceutically acceptable carrier;
wherein the expression vector expresses the precursor sequence of
7. A method for administering a pharmaceutical composition, comprising
administering the pharmaceutical composition of
8. A pharmaceutical composition, comprising
the precursor sequence of
an expression vector, which comprises said precursor sequence or a polynucleotide that can be transcribed by a host to form said precursor sequence, and
a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of
the dosage form of the pharmaceutical composition comprises a tablet, a capsule, a powder, a pill, a granule, a syrup, a solution, a suspension liquid, an emulsion, a suspension, an injection solution, or an injectable powder.
10. The pharmaceutical composition of
12. A method for inhibiting K-RAS or for treating a malignant tumour highly expressing K-RAS;
wherein the malignant tumour is selected from the group consisting of kidney cancer, oral epithelial cancer, head and neck cancer, bladder cancer, brain tumour, glioblastoma, liver cancer, lung cancer, stomach cancer, oesophageal cancer, ovarian cancer, colorectal cancer, cervical cancer, pancreatic cancer, prostatic cancer, leukaemia and breast cancer,
comprising administering to a subject in need thereof an effective amount of the precursor sequence of
an expression vector, comprising said precursor sequence or a polynucleotide that can be transcribed by a host to form said precursor sequence, or
an sirna capable of inhibiting expression of a K-RAS gene, wherein the nucleotide sequence of the sense strand of the sirna is seq id NO: 263, and to which directly or indirectly a sequence a1 and/or A2 is attached, wherein a1 is UGCUG and A2 is CAGG or CAGGA.
13. The pharmaceutical composition of
14. The pharmaceutical composition of
15. The pharmaceutical composition of
16. The pharmaceutical composition of
17. The pharmaceutical composition of
18. The method according to
19. The precursor sequence of
|
|||||||||||||||||||||||||||||||||||||||||||
The present invention belongs to the biomedical field, and specifically pertains to a siRNA which inhibits the K-RAS gene expression, and the precursors and applications thereof.
RNA interfering (RNAi) is a powerful experimental tool in the laboratory, using double-stranded RNA (dsRNA) having homology to induce the sequence-specific silencing of a target gene, thereby rapidly blocking its activity. The siRNA plays a central role in the RNA silencing pathway and is a guiding element for the degradation of a specific messenger RNA (mRNA). siRNA is an intermediate product in the RNAi pathway and is an essential factor for RNAi to exert effects. The formation of siRNA is mainly regulated by Dicer and Rde-1. Due to RNA virus invasion, transposon transcription, reverse repeat sequence transcription in the genome and other factors, dsRNAs appear in the cell, and the protein encoded by Rde-1 (RNAi deficient gene-1) recognizes the foreign dsRNA. When the level of dsRNA reaches a certain amount, Rde-1 guides the dsRNA to bind to Rde-1 encoded Dicer (Dicer is an RNaseIII active endonuclease with four domains: PAZ domain of the Argonaute family, type III RNase active region, a dsRNA binding region and a DEAH/DEXHRNA helicase active region), forming an enzyme-dsRNA complex. The siRNA forms after cleavage by Dicer, and then, with the participation of ATP, a RNA-induced silencing complex (RISC) is formed in the cell. A key step in RNAi is to assembly RISC and synthesize siRNA protein mediating specific reaction. siRNA is incorporated into RISC and then degrades a target gene by fully pairing with the coding region or a UTR of it, thus saying that a siRNA only degrades the mRNA that is in complementary pair with the sequence of the siRNA. The mechanism of its regulation is to silence the expression of the corresponding target gene through complementary pairing, and is thus a typical negative regulation mechanism. The siRNA recognition of the target sequence is highly specific, since degradation occurs first in a relatively central position of the siRNA, and therefore these central base sites are extremely important and the effect of RNAi can be severely inhibited in the event of a mismatch. As an emerging therapeutic technology, siRNA has also entered the clinical trial stage at an unprecedented rate.
K-RAS is one member of the RAS gene family, encoding the K-RAS protein. It is related to the formation, proliferation, migration, metastasis and angiogenesis of tumour.
K-RAS protein has GTPase activity, which is in an activated state when it is bound with GTP and in an inactivated state when it is bound with GDP. The K-RAS protein mainly localizes itself on the cell membrane. After the K-RAS protein is phosphorylated by PKC, this phosphorylation process causes the localization change of K-RAS protein due to the weakening of the binding of K-RAS protein to the cell membrane, and then movement to positions such as the endoplasmic reticulum, Golgi apparatus and mitochondria, and etc. The K-RAS protein serves as a molecular switch and plays an important role in many signalling pathways.
Research has shown that about 30% of human malignancies are associated with RAS gene mutations, and products of mutated RAS can remain in an activated state. K-RAS mutations are common in leukaemia, lung cancer, rectal cancer and pancreatic cancer, with 30%-35% of patients with rectal cancer having the mutations. They are associated with the survival, proliferation, migration, metastasis and angiogenesis of tumour cells. K-RAS genes are divided into mutant types and wild type, and the common mutation sites are codons 12 and 13 on the K-RAS gene exon 2, and codon 61 of the exon 3, wherein there are 7 mutation hotspots: G12C, G12R, G12S, G12V, G12D, G12A, and G13V/D. These 7 types account for 90% or more of the mutations.
The current EGFR targeted drugs on the market are mainly: Gefitinib (Iressa), erlotinib (Tarceva), Cetuximab (ERBITUX), panitumumab (Vectibix). However, EGFR targeted drugs are very ineffective for patients with K-RAS mutations, because even though there is no EGFR signal, K-RAS is still in an activated state to transmit signals downstream, so in personalized medication it is necessary to detect the K-RAS gene state and then select the drug. If K-RAS is of a mutant type, it is not recommended to use EGFR targeted drugs.
Therefore, considering that if the EGFR and K-RAS pathways can be targeted at the same time, then the upstream and downstream of the pathway can be simultaneously inhibited, thereby producing a better therapeutic effect by the EGFR targeted drug on patients with K-RAS mutations. Therefore, there is an urgent need for a treatment method and corresponding drugs that can targetedly inhibit of the K-RAS gene to solve the current problems such as the absence of drugs specific for the K-RAS mutation, and E′GFR targeted drugs are ineffective due to the K-RAS mutation.
The present invention provides a novel siRNA that inhibits the K-RAS gene, and precursors and applications thereof in the treatment of tumours.
The first aspect of the invention provides a precursor sequence, characterised in that it has a structure from the 5′ terminus to the 3′ terminus as shown in formula I:
##STR00001##
wherein B1 is a first ribonucleic acid sequence as desired, comprising a K-RAS siRNA sense strand sequence;
B2 is a sequence with substantial or complete complementarity to B1, and B2 is not complementary to C;
C is a stem-loop structure sequence, preferably GUUUUGGCCACUGACUGAC;
A1 and A2 are null, or are optionally RNA sequences consisting of 4-5 bases, respectively;
wherein the nucleotide sequence of the K-RAS siRNA sense strand is selected from the following sequences as shown in the sequence listing: SEQ ID NO: 3, SEQ ID NO: 26, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 52, SEQ ID NO: 73, SEQ ID NO: 88, SEQ ID NO: 98, SEQ ID NO: 101, and SEQ ID NO: 106 or SEQ ID NO: 263;
In another preferred example, there are 2-8, preferably 3-5 non-complementary bases between the B2 and B1.
In another preferred example, 1-2 bases are added or deleted in the B2 as compared with the B1.
In another preferred example, 1-2 bases, preferably 2 bases, are deleted in the B2 as compared with the B1.
In another preferred example, the said deleted 1-2 bases are in the middle of B1, i.e., 1-2 bases at positions 9-14, such as positions 9-10, 10-11, 11-12, 12-13 or 13-14.
In another preferred example, the A1 is UGCUG; and/or the A2 is CAGG or CAGGA.
In another preferred example, A2 is preferably CAGG.
The second aspect of the present invention provides a polynucleotide, which can be transcribed by a host to form the precursor sequence of the first aspect of the present invention.
The third aspect of the present invention provides an expression vector containing the precursor sequence of the first aspect of the present invention, or the polynucleotide of the second aspect of the present invention.
In another preferred example, the expression vector comprises a viral vector and a non-viral vector.
In another preferred example, the expression vector is a plasmid.
In another preferred example, the upstream of the polynucleotide of the second aspect of the present invention is a promoter, and the downstream thereof is a TKPA element.
The fourth aspect of the present invention provides a pharmaceutical preparation comprising:
(a) an expression vector for expression of a K-RAS siRNA sequence; and
(b) a pharmaceutically acceptable carrier. In another preferred example, the K-RAS siRNA sequence is selected from the sequences group: SEQ ID NO: 3, SEQ ID NO: 26, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 52, SEQ ID NO: 73, SEQ ID NO: 88, SEQ ID NO: 98, SEQ ID NO: 101, and SEQ ID NO: 106 or SEQ ID NO: 263.
In another preferred example, the said expression vector expresses the precursor as shown in formula I,
##STR00002##
Wherein, B1 is a first ribonucleic acid sequence as desired, comprising a K-RAS siRNA sense strand sequence;
B2 is a sequence with substantial or complete complementarity to B1, and B2 is not complementary to C;
C is a stem-loop structure sequence; and
A1 and A2 are null, or are optionally RNA sequences consisting of 4-5 bases, respectively;
In another preferred example, the first ribonucleic acid sequence is a K-RAS siRNA sense strand, and the second ribonucleic acid sequence is a K-RAS siRNA antisense strand.
In another preferred example, the preparation is in a liquid dosage form.
In another preferred example, the preparation is an injection.
In another preferred example, the expression vector comprises a plasmid.
In another preferred example, the expression vector or plasmid contains a promoter, an origin of replication and a marker gene.
In another preferred example, the expression vector contains an expression cassette expressing the K-RAS siRNA.
In another preferred example, the expression cassette (i.e., a polynucleotide) is double-stranded, and has the following structure:
a promoter-attB1—an optional tag protein (such as GFP or emGFP)—a 5′ siRNA flanking region sequence—the sequence as shown in formula I—a 5′ siRNA flanking region sequence-attB2—an optional TKPA element.
In another preferred example, the preparation is a liposome preparation.
The fifth aspect of the present invention provides a method for administering a medicament, comprising the step of:
administering the pharmaceutical preparation of the fourth aspect of the present invention at a first site of a mammal, so that the expression vector is processed to form microvesicles in the mammal, which are transported to a second site on the mammal where the siRNA is expressed.
In another preferred example, the said mammal comprises human and non-human mammals.
In another preferred example, the said first site comprises a subcutaneous, intravenous or gastrointestinal tract site.
In another preferred example, the said second site comprises liver, lung, and kidney.
In another preferred example, the said administering comprises oral intake, subcutaneous injection, intramuscular injection and intravenous injection.
The sixth aspect of the invention provides an siRNA for inhibiting K-RAS gene expression, wherein the nucleotide sequence of the siRNA sense strand is selected from the following sequences as shown in the sequence listing: SEQ ID NO: 3, SEQ ID NO: 26, SEQ ID NO: 41, SEQ ID NO: 47, SEQ ID NO: 52, SEQ ID NO: 73, SEQ ID NO: 88, SEQ ID NO: 98, SEQ ID NO: 101, and SEQ ID NO: 106 or SEQ ID NO: 263.
In another preferred example, the said nucleotide sequence of the siRNA sense strand is shows as SEQ ID NO: 263 in the sequence listing.
The seventh aspect of the present invention provides a pharmaceutical composition comprising the precursor sequence of the first aspect of the present invention, the expression vector of the third aspect of the present invention, or the siRNA of the sixth aspect of the present invention, and a pharmaceutically acceptable carrier.
In another preferred example, the pharmaceutical composition includes the K-RAS siRNA plasmid.
In another preferred example, the pharmaceutical composition also includes EGFR targeted drugs.
In another preferred example, the pharmaceutical composition is the expression vector of the third aspect of the present invention, and preferably is a plasmid containing the precursor sequence of the first aspect of the present invention.
In another preferred example, the dosage form of the pharmaceutical composition comprises:
a tablet, a capsule, a powder, a pill, a granule, a syrup, a solution, a suspension liquid, an emulsion, a suspension, an injection solution, or an injectable powder.
In another preferred example, the dosage form of the pharmaceutical composition further comprises a spray, an aerosol, a powder spray, a volatile liquid, a topical solution, a lotion, a pour-on agent, a liniment, a cataplasma, a medicinal paste, a rubber paste, an ointment, a plaster, a paste, an eye drop, a nasal drop, an ophthalmic ointment, a mouth wash, a sublingual tablet, or a suppository.
In another preferred example, the dosage form is an injection, preferably an intravenous injection or an intraperitoneal injection.
The eighth aspect of the present invention provides the use of the siRNA of the first aspect of the present invention, of the precursor sequence of the first aspect of the present invention or of the expression vector of the third aspect of the present invention, comprising the use: (i) for preparing an inhibitor of K-RAS; and/or (ii) for preparing a pharmaceutical composition against a malignant tumour highly expressing K-RAS.
In another preferred example, the malignant tumour comprises kidney cancer, oral epithelial cancer, head and neck cancer, bladder cancer, brain tumour, glioblastoma, liver cancer, lung cancer, stomach cancer, oesophageal cancer, ovarian cancer, colon cancer, rectal cancer, cervical cancer, pancreatic cancer, prostatic cancer, leukaemia or breast cancer.
The ninth aspect of the present invention provides a method for inhibiting the growth of malignant tumour cells highly expressing K-RAS in a non-therapeutic manner in vitro, comprising the steps of:
culturing the malignant tumour cells highly expressing K-RAS in the presence of the pharmaceutical composition of the seventh aspect of the present invention, so as to inhibit the growth of malignant tumour cells highly expressing K-RAS.
The tenth aspect of the present invention provides a method for treating malignant tumour highly expressing K-RAS, which involves administering a safe and effective amount of the expression vector of the third aspect of the present invention, or the pharmaceutical composition of the seventh aspect of the present invention, to a subject in need, so as to treat diseases associated with highly expressed K-RAS.
In another preferred example, the administered dosage is 0.05-10 mg/kg, preferably 0.1-5 mg/kg.
In another preferred example, the administering comprises oral, respiratory tract, injection, transdermal, mucosal, or cavity administration.
In another preferred example, the administering comprises plasmid injection.
The eleventh aspect of the present invention provides a method for treating diseases associated with highly expressed K-RAS, characterized in that the method involves administering the K-RAS siRNA plasmid containing the precursor sequence of the first aspect of the present invention by intravenous injection to a subject in need, so as to treat the diseases associated with highly expressed K-RAS.
It should be understood that all of the various technical features described above and specifically described hereinafter (such as the examples) can be combined with one another within the scope of the present invention, so as to form new or preferred technical solutions. Due to space limitations, these are no longer tired out one by one.
The inventor initiates the design and preparation of precursor siRNAs capable of efficiently expressing the K-RAS siRNAs by extensive and deep studies. The precursor siRNAs of the present invention, after having been processed by a host cell, can efficiently express the K-RAS siRNAs, so as to effectively avoid the interference effect of the reverse complementary sequence of a target sequence on the functioning of the target sequence. The experiment demonstrated that the precursor siRNAs of the present invention can efficiently express the K-RAS siRNA sequences, and have a more effective therapeutic effect on various malignant tumours. The present invention is accomplished on this basis.
siRNAs and its Precursors
As used herein, the “siRNAs” refer to a class of RNA molecules, which are obtained by processing transcripts which can form siRNA precursors. The mature siRNAs generally have 18-26 nucleotides (nt) (more specifically, about 19-22 nt), not excluding siRNA molecules having other numbers of nucleotides. siRNAs are usually detectable by northern blotting.
The siRNAs derived from humans can be isolated from human cells. As used herein, “isolated” means that the substance is isolated from its original environment (if it is a natural substance, the original environment is the natural environment). For example, polynucleotides and polypeptides in the natural environment of living cells are not isolated and purified, but when the same polynucleotides or polypeptides are isolated from other substances coexisting in the natural environment, they are isolated and purified.
siRNAs can be obtained by processing the precursor siRNAs, and the said precursor siRNAs can be folded into a stable stem-loop (hairpin) structure having a general length of 50-100 bp. The said precursor siRNAs can be folded into a stable stem-loop structure, and two sides of the stem of the stem-loop structure contain two sequences substantially complementary to each other.
In the present invention, the said precursor siRNAs are artificially synthesised precursor siRNAs, and the said precursor siRNAs have the structure as shown in formula I:
##STR00003##
As a representative example, B1 is K-RAS siRNA sense strand sequence;
B2 is a sequence with complementarity (including substantial and complete complementarity) to B1;
C is a sequence as shown (GUUUUGGCCACUGACUGAC);
A1 and A2 are null or optionally nucleotide sequences consisting of 4-5 bases respectively;
wherein the precursor siRNA as shown can be processed in the host to form the K-RAS siRNA.
In the present invention, the precursor siRNA forming K-RAS siRNA can be spliced to generate an siRNA regulating the K-RAS, i.e. the K-RAS siRNA (for example SEQ ID NO.: 263).
In Formula I, B2 and B1 have substantial complementarity to each other. As used herein, “substantial complementarity” means that the nucleotide sequence is sufficiently complementary and that same can act upon each other in a predictable manner, e.g., forming a secondary structure (such as a stem-loop structure). Generally, at least 70% of nucleotides in two “substantially complementary” nucleotide sequences are complementary; preferably, at least 80% of nucleotides are complementary; and more preferably, at least 90% of nucleotides are complementary. Generally, there are at most 8 non-matched nucleotides, preferably 1, 2, 3, 4 and 5 non-matched nucleotides, between two sufficiently complementary molecules.
As used in the present application, the “stem-loop” structure, also known as the “hairpin” structure, refers to a nucleotide molecule which can form a secondary structure comprising a double-stranded region (stem) formed of two regions (on a same molecule) of this nucleotide molecule, the two regions being at two sides of the double-stranded part; and the structure further comprises at least one “loop” structure, including non-complementary nucleotide molecules, i.e., a single-stranded region. Even if the two regions of the nucleotide molecule are not completely complementary, the double-stranded part of the nucleotide can also maintain the double-stranded form. For example, insertion, deletion, substitution or the like may lead to a non-complementary small region or make the small region itself form a stem-loop structure or another form of secondary structure. However, the two regions can still be substantially complementary to each other and act upon each other in a predictable manner to form a double-stranded region of the stem-loop structure. The stem-loop structure is well known to a person skilled in the art, who can generally determine, when given a nucleic acid having a nucleotide sequence of the primary structure, whether the nucleic acid can form a stem-loop structure.
In the present invention, a “stem-loop structure” can be present at the end of the precursor siRNAs as shown in Formula I, for example, after B1 and B2 form a substantially complementary structure, C will form a stable stem-loop structure at the end thereof; the “stem-loop structure” can also be present in the interior of the precursor siRNAs as shown in Formula I, for example, since B1 and B2 are not completely complementary, the bases in B1 or B2 which do not bind with the others in a complementary manner will form an internal loop.
Highly expressing K-RAS as used herein refers to highly expressing the K-RAS protein, or highly expressing the K-RAS mRNA.
Referring to the siRNA sequences provided in the present invention, polynucleotide constructs, which can, after introduction, be processed into siRNAs capable of affecting the expression of the corresponding mRNAs, can be designed, i.e., the polynucleotide constructs can up-regulate the level of the corresponding K-RAS siRNAs in vivo so as to decrease the expression amount of K-RAS. Therefore, the present invention provides an isolated polynucleotide (construct), and the polynucleotide (construct) can be transcribed by human cells into precursor siRNAs which can be spliced and expressed as the siRNAs in human cells.
Polynucleotide Constructs
As a preferred mode of the present invention, the polynucleotide construct contains a structure from the 5′ terminus to the 3′ terminus as shown in formula II:
a1-b1-c-b2-a2 Formula II
In Formula II,
b1 is a nucleotide sequence which can be expressed as the K-RAS siRNA in a cell, b2 is a nucleotide sequence substantially or completely complementary to b1; c is a spacer sequence between b1 and b2, and the spacer sequence is not complementary to B1 and B2;
a1 and a2 are null or optionally nucleotide sequences consisting of 4-5 bases respectively;
and after being introduced into the cell, the structure as shown in formula II forms a secondary structure as shown in formula I:
##STR00004##
Generally, the polynucleotide constructs are located on the expression vector. Therefore, the present invention further includes a vector containing the siRNAs or the polynucleotide constructs. The expression vector typically further contains a promoter, an origin of replication and/or a marker gene, etc. Methods well known to a person skilled in the art can be used to construct the expression vector required by the present invention. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. The expression vector preferably contains one or more selectable marker genes to provide a phenotypic trait for the selection of transformed host cells, such as kanamycin, gentamicin, hygromycin or ampicillin resistance.
In the present invention, there is no special limitation on the said expression vector, including commercially available or conventionally prepared expression vectors. Representative examples include (but are not limited to): pcDNATM6.2-GW/miR, pcDNA3, pMIR-REPORT miRNA, pAdTrack-CMV, pCAMBIA3101+pUC-35S, pCMVp-NEO-BAN, pBI121, pBin438, pCAMBIA1301, pSV2, a CMV4 expression vector, pmiR—RB-Report™, pshOK-basic, mmu-mir 300-399 miRNASelect™, pshRNA-copGFP Lentivector, GV317, GV309, GV253, GV250, GV249, GV234, GV233, GV232, GV201, GV159 or other expression vectors of the GV series.
In another preferred example, in the said expression vector, the promoter operably linked to the polynucleotide expressing the precursor siRNAs includes a constitutive promoter or a tissue-specific promoter, preferably a liver tissue-specific promoter. In other words, these promoters are used to drive the expression of the precursor siRNAs.
Representative promoters includes (but are not limited to): a Pcmv promoter, U6, H1, a CD43 promoter, a CD45 (LCA) promoter, a CD68 promoter, an Endoglin (CD105) promoter, a Fibronectin promoter, an Flt-1 (VEGFR-1) promoter, a GFAP promoter, a GPIIb (Integrin αIIb) promoter, an ICAM-2 (CD102) promoter, an MB (Myoglobin) promoter, an NphsI (Nephrin) promoter, an SPB promoter, an SV40/hAlb promoter, an SYN1 promoter, a WASP promoter or a combination thereof.
Pharmaceutical Composition and Administration Methods
As used herein, the term “effective amount” or “effective dose” refers to the amount which can induce a function or activity in humans and/or animals and can also be acceptable to humans and/or animals.
As used herein, the term “pharmaceutically acceptable” component is applicable to human and/or mammals without excessive adverse side effects (such as toxicity, irritation and allergic responses), i.e., a substance with a reasonable benefit/risk ratio. The term “pharmaceutically acceptable carrier” refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
The pharmaceutical composition of the present invention contains a safe and effective amount of the active component of the present invention and a pharmaceutically acceptable carrier. Such carrier includes, but is not limited to, saline, a buffer, glucose, water, glycerol, ethanol, and a combination thereof. Generally, a pharmaceutical preparation shall match the administration mode, and the dosage form of the pharmaceutical composition of the present invention can be an injection, an oral preparation (a tablet, a capsule, or an oral liquid), a transdermal agent, or a slow release agent. For example, preparation thereof is performed by a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants. The pharmaceutical composition is preferably produced under sterile conditions.
The effective amount of the active component of the present invention may vary depending on the administration mode and the severity of the disease to be treated. A person skilled in the art could determine the selection of the preferred effective amount depending on various factors (e.g., by clinical trials). The factors include, but are not limited to, the pharmacokinetic parameters of said active component, e.g., the bioavailability, metabolism, half-life, etc.; and the severity of the patient's disease to be treated, the patient's weight, the patient's immune state, the administration route, etc. Generally, when the active component of the present invention is administered at a dose of about 0.00001-50 mg/kg body weight (preferably 0.0001-10 mg/kg body weight) per day, satisfactory results can be achieved. For example, due to the urgent requirements of the treatment status, several separate doses can be administered daily, or the dosage can be reduced proportionally.
The pharmaceutically acceptable carrier of the present invention includes (but is not limited to): water, saline, liposomes, lipids, micro particles, micro vesicles, exosomes, shedding vesicles, nanocapsules/nanoparticles, β-cyclodextrin capsule (β-cyclodextriniclusion compound) proteins, protein-antibody conjugates, peptides, cellulose, nanogels, or a combination thereof. The choice of carriers should match the administration mode, which is well known to a person skilled in the art.
In the present invention, the said expression vector can be directly administered to a subject, and the expression vector can also be administered by preparing same into a pharmaceutical composition with a pharmaceutically acceptable carrier. The administration comprises intravenous injection.
Therapeutic Method
The present invention also provides a method for treating diseases associated with the expression amount of the K-RAS siRNA, that is, administering a safe and effective amount of the expression vector or the pharmaceutical composition of the present invention to a subject in need, so as to treat diseases associated with the K-RAS activity. Generally, “a disease associated with the expression amount of the K-RAS siRNA” means that there is a significant difference in the expression amount (or activity) E1 of the K-RAS protein or mRNA, and the K-RAS amount (or activity) E0 in the paracancerous tissue or normal tissue in a patient with the disease, and preferably, the high expression refers to E1≥1.5 E0, and more preferably E1≥2 E0. In tumour tissue, whether K-RAS is highly expressed can be detected by conventional methods. Generally, the malignant tumours highly expressing K-RAS include (but are not limited to) liver cancer, lung cancer, stomach cancer, oesophageal cancer, ovarian cancer, colorectal cancer, cervical cancer, pancreatic cancer, prostatic cancer, leukaemia or breast cancer.
The precursor siRNAs of the present invention can effectively avoid the over-expression of the reverse complementary sequence of a target sequence along with the over-expression of the target sequence, so as to effectively avoid the interference effect of the reverse complementary sequence of a target sequence on the functioning of the target sequence.
The precursor siRNAs of the present invention can efficiently express K-RAS siRNA sequences, and have an effective therapeutic effect on various malignant tumours, and can thereby be used in the development of novel tumour therapeutic drugs.
The present invention is further illustrated in connection with particular embodiments as follows. It should be understood that these embodiments are merely illustrative of the invention and are not intended to limit the scope of the present invention. In the case of specific conditions for the experimental method being not specified in the following examples, generally conventional conditions are followed, such as the conditions described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbour Laboratory Press, 1989), or the conditions recommended by the manufacturer are followed. All percentages and portions are of weight unless otherwise indicated.
Out of biosafety reasons, the plasmid was first modified. Biologically toxic elements, such as EmGFP and Blasticidin, were cut with DNA restriction endonucleases.
pCMV represents a eukaryotic promoter, pUC ori represents the replication origin of the plasmid in prokaryotic cells which does not express an insertion sequence, and Spectinomycin represents the spectinomycin resistance gene for plasmid screening.
After the plasmid modification, a complementary oligo DNA is designed and synthesised according to the K-RAS gene sequence. The K-RAS siRNA sequence was as follows: 5′-GGUGACUUAGGUUCUAGAU-3′ (SEQ ID NO: 263). The sequences are as shown in Table 1.
TABLE 1
The oligo DNA sequences and their corresponding precursor siRNA elements
Oligo
name
Oligo DNA sequence 5′-3′
> K-RAS siRNA mature sequence: 5′-GGUGACUUAGGUUCUAGAU-3′
13MR0041-
TGCTGAATTCGGTGACTTAGGTTCTAGATGTTTTGGCCACTGACTGACATCTAGAATAAGT
1F
CACCA
| A1 | B1 | C | B2 |
TGCTGAATTCGGUGACUUAGGUUCUAGAUGTTTTGGCCACTGACTGACATCTAGAATAAG
TCACCA)
13MR0041-
CCTGACCGGTGGTGACTTATTCTAGATGTCAGTCAGTGGCCAAAACATCTAGAACCTAAG
1R
TCACC
| A2 | B2 | C | B1 |
CCTGACCGGTGGTGACTTATTCTAGATGTCAGTCAGTGGCCAAAACATCTAGAACCTAAG
TCACC)
Negative control sequence
Negative-
tgctgAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTACATTT
F
|A1 | multiple cloning site | C | multiple cloning site |
tgctgAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTACAT
TT)
Negative-
cctgAAATGTACTGCGTGGAGACGTCAGTCAGTGGCCAAAACGTCTCCACGCGCAGTACATTTc
R
|A2| multiple cloning site | C | multiple cloning site |
cctgAAATGTACTGCGTGGAGACGTCAGTCAGTGGCCAAAACGTCTCCACGCGCAGTACATT
Tc)
Then the synthesised oligo single-stranded DNAs were dissolved in ddH2O to 100 μM, and 5 μl of each of the complementary single strands were taken and mixed pairwise, and annealed in the system given in Table 2. 2 portions of the oligo mixture were heated at 95° C. for 5 minutes, and then placed at room temperature for 20 minutes to form double-stranded DNAs.
TABLE 2
Oligo DNA annealing system
100 μM top strand oligo
5 μl
100 μM bottom strand oligo
5 μl
10 × oligo annealing buffer
2 μl
ddH2O
8 μl
Total volume
20 μl
The annealed double-stranded DNAs were then diluted to a concentration of 10 nM, and ligated at room temperature in the system given in Table 3 for 30 minutes.
TABLE 3
Enzyme ligation system
5 × ligation buffer
4 μl
pcDNA6.2-GW/EmGFP-miR
2 μl
ds oligo (10 nM)
4 μl
T4 DNA ligase (1 U/μl)
l μl
ddH2O
9 μl
Total volume
20 μl
100 μl competent cells were transformed with 10 μl ligated product, followed by spreading on LB plates (containing 50 μg/ml spectinomycin) and incubating at 37° C.
Wherein the strain of competent cells can be E. coli DH5α, XL10-GOLD, BB4, DE3, BM25.5, BMH71-18mutS, BW313, C-la, C600, DH1, DH5, DP50supF, ED8654, ED8767, ER1647, HB101, HMS174, JM83, JM101, JM105, JM106, JM107, JM108, JM109, JM110, K802, K803, LE392, MC1061, MV1184, MV1193, NovaBlue, RR1, TAP90, TG1, TG2, XL1-Blue, x1776, Y-1088, Y-1089, Y-1090 and the like.
E. coli DH5a or XL10-GOLD can be preferred in the above strains, and E. coli DH5α is the most preferable.
3 clones were respectively picked from each transformation plate, followed by shaking same and extracting plasmids therefrom, and sequencing to validate whether the inserted fragment sequence in the recombinant clones was consistent with the designed oligo single-stranded DNA sequence or not.
LLC (Lewis Lung Cancer) cell line was provided by School of Life Sciences, Nanjing University. DMEM is a product from Hyclone Corporation. Fetal calf serum is a product from Gibco Corporation. In experiments, LLC cell line was cultured in DMEM complete media containing 10% FBS, 100 ug/ml penicillin and 100 ug/ml streptomycin, in an incubator at 37° C. and with 5% CO2.
Experimental animals were 15 6-week-old C57BL/6 mice, half male and half female, provided by the Model Animal Institute, Nanjing University.
LCC cells were first cultured, and the LCC cells grown to the logarithmic phase were digested with pancreatin, followed by centrifuging at 1000 rpm, discarding the supernatant, washing twice with sterile normal saline, suspending the cells in normal saline, trypan blue staining for observing the cell viability, performing the cell counting, and adjusting the cell density to 5×106 cells/ml. In experiments, healthy C57BL/6 mice were taken and injected at 0.2 ml/mouse through tail-vein slowly, and after the injection was finished, all the modelled mice were divided into:
group 1: mice injected with PBS through the tail-vein slowly (negative control group);
group 2: mice injected with the control plasmid (5 mg/kg) through the tail-vein slowly; and
group 3: mice injected with the K-RAS siRNA plasmid (5 mg/kg) through the tail-vein slowly.
In addition, another group of normal mice was taken and used as the normal control. During the model construction, the spirit, dietary statuses, defecation, body weights, activities and other conditions of C57BL/6 mice were observed periodically. Starting from day 14, the mice were administered with 0.1 ml/10 g body weight by intravenous tail injection, and the control group was administered with the corresponding amount of normal saline. During administration, the mice were administered with same once every 3 days, 7 times in total. On day 3 after the last administration, the mice were anaesthetized with diethyl ether, followed by taking the blood, lung and liver. The lung and liver were placed in 10% formalin, pathological sections were made, and the lung cancer model construction situation, and the treatment situation of the K-RAS siRNA plasmid on the lung cancer were observed.
During model construction, the living conditions of all animals were good, and adverse effects such as piloerection, dull-looking, abnormal respiration, slow activity and abnormal stool were not seen.
All the measurement data were expressed as
Two weeks after the C57BL/6 mice were used for Lewis lung cancer model construction, the K-RAS siRNA plasmid was administered by intravenous injection for treatment; during administration, the mice were administered with same once every 3 days; and the animals were sacrificed on day 3 after the final administration, for taking the blood, lung, liver and various tissues and organs. The K-RAS siRNA content in various tissues and organs was detected by qRT-PCR.
Besides those for the detection of molecular indicators, the rest of the lung and liver were fixed with formalin, and pathological tissue sections were prepared for examining the tumour situations of the organs. The results of the pathological sections are shown in
The results above showed that the K-RAS siRNA plasmid can significantly reduce the expression level of the K-RAS protein in the lung tumour tissues.
Furthermore, we combined the results of all pathological sections to score the severity of lung tumours (results as shown in
After successful model construction of mouse lung cancer, treatment was performed as the following grouping: control group 1: mice injected with PBS (phosphate buffer) through the tail-vein slowly; control group 2: mice injected with control plasmid (5 mg/kg) (control plasmid not expressing effective K-RAS siRNA precursors) through the tail-vein slowly; experimental group: mice injected with the K-RAS siRNA plasmid (5 mg/kg) through the tail-vein slowly. In addition, another group of normal mice was taken and used as a normal control (Normal).
After treatment, the severity of lung cancer in K-RAS siRNA plasmid mice was significantly lower than that in the two control groups (PBS and control plasmid), and even some mice were completely cured, showing the therapeutic effect of the K-RAS siRNA plasmid on lung tumours.
During the treatment, we performed imagological examination on lung tumours in mice utilizing Bruker's Skyscan micro-CT device, and analysed the data using matching statistical software CTAn, to further confirm the therapeutic effect of the KRAS siRNA plasmid on lung tumours. The tumour diameters are as statistically shown in
Conclusion
The K-RAS siRNA plasmid had a therapeutic effect on the mouse Lewis lung cancer in vivo, and the abnormal responses related with the medication were not seen during administration.
Colon cancer cell line: mouse colon cancer cell line CT-26 (derived from BALB/c, H-2Kd) provided by the College of Life Sciences, Nanjing University.
Experimental animals for model construction: 6-7 week-old female BALB/c mice provided by the Model Animal Institute, Nanjing University.
Animal model construction: BALB/c mice were the same species of animals as the CT-26 tumour cell line. The recovered CT-26 cells were subcultured. When the cells grew to a certain amount, cells in logarithmic growth phase were taken and 0.9% normal saline was added to adjust the cell concentration to 5×106/ml, the tumour cells were inoculated in the right axilla of the mice subcutaneously at a dose of 0.2 ml/mouse (about 1×106 cells/mouse), and the mice were fed with a normal diet after inoculation.
1 week later, tumour growth was observed in the axilla of all 15 tumour-bearing BALB/c mice, i.e., the model construction was successful. 15 mice were selected and randomly divided into:
group 1: mice injected with PBS in the left axilla subcutaneously (the negative control group);
group 2: mice injected with control plasmid (5 mg/kg) in the left axilla subcutaneously; and
group 3: mice injected with the K-RAS siRNA plasmid (5 mg/kg) in the left axilla subcutaneously.
In addition, another group of normal mice was taken and used as a normal control (Normal).
During model construction, the living status, tumour size and appearance of the BALB/c tumour-bearing mice were observed periodically. Starting from day 8, the mice were administered with 0.1 ml/10 g body weight by intravenous tail injection, and the control group was administered with the same amount of normal saline. During administration, the mice were administered with same once every 3 days, 7 times in total. On day 3 after the final administration, all the mice were sacrificed by spinal dislocation, the skin was incised quickly at the site of tumour growth, and the tumour was completely excised.
The therapeutic effect of the K-RAS siRNA plasmid on the mouse colon cancer was then verified.
1. The effect of the K-RAS siRNA plasmid on the volume of colon cancer subcutaneous transplanted tumours in mice
The long diameter (a) and short diameter (b) of tumours were measured with a vernier caliper, and the tumour volume V (mm3) was calculated as 1/6πab2. After the measurement, the tumours were fixed in 10% formaldehyde.
The tumour inhibition rate was calculated: tumour inhibition rate (%)=(V in control group−V in experimental group)/V in control group×100%.
Compared with the tumour volume in group 1 and group 2, the volume in group 3 was significantly smaller (P<0.05), as shown in Table 4 below.
TABLE 4
Tumour volumes and tumour inhibition rates in different
groups of experimental mice
Tumour
volume
average Tumour
Group n
(V/mm3)
inhibition rate (%)
Group 1
3768.15 ± 696.13
0
Group 2
3659.73 ± 951.13
0
Group 3
2392.75 ± 559.21
34.6%*, 36.5%#
*Relative to group 2,
#relative to group 1
The K-RAS siRNA content in the transplanted tumours was detected by qRT-PCR, and the results showed that the K-RAS siRNA entered the transplanted tumours.
The expression level of the K-RAS mRNA in the transplanted tumours was then detected, and the experimental results (
The tumour tissue proteins were extracted, and the expression level of the K-RAS protein in tumour tissues was detected using a western blotting experiment. It was found from the experimental results (see
The K-RAS siRNA plasmid had a therapeutic effect on the colon cancer in vivo, and the abnormal responses related with the medication were not seen during administration.
PATU8988, a human pancreatic cancer cell line, was provided by ATCC.
RPMI-1640 complete medium and fetal bovine serum were provided by GIBCO. In the experiment, the human pancreatic cancer cell line was placed in 10% RPMI-1640 complete medium and cultured in an incubator at 37° C., 5% CO2; the medium was changed once every 2 days; and on days 2-3, the cells were digested with 0.25% trypsin and subcultured at a ratio of 1:3.
The experimental animals were 15 half-male and half-female 6-week-old nude BALB/c (nu/nu) mice provided by Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.
When the human pancreatic cancer cells fully cover the bottom of the bottle, the single cell suspension was collected, and the mice were injected with 0.2 ml at 5×106 tumour cells/mouse into the pancreas in situ to establish a tumour model.
The pancreatic cancer mice were randomly divided into three groups:
group 1: mice injected with PBS through the tail-vein slowly (negative control group);
group 2: mice injected with the control plasmid (5 mg/kg) through the tail-vein slowly; and
group 3: mice injected with the K-RAS siRNA plasmid (5 mg/kg) through the tail-vein slowly.
In addition, another group of normal mice was taken and used as the normal control. During model construction, the spirit, dietary status, defecation, body weight, activity and other conditions of the nude BALB/c (nu/nu) mice were observed periodically. Starting from day 14, the mice were administered with 0.1 ml/10 g body weight by intravenous tail injection, and the control group was administered with the corresponding amount of normal saline. During administration, the mice were administered with same once every 3 days, 7 times in total. On day 3 after the last administration, the mice were anaesthetized with diethyl ether, followed by taking the blood, pancreas and liver. The pancreas and liver were placed in 10% formalin, pathological sections were made, and the pancreatic cancer model construction situation and the treatment effect of the K-RAS siRNA plasmid on the pancreatic cancer were observed.
Two weeks after the BALB/c (nu/nu) mice were used for human pancreatic cancer model construction, the K-RAS siRNA plasmid was administered by intravenous injection for treatment; during administration, the mice were administered with same once every 3 days; and the animals were sacrificed on day 3 after the final administration, for taking the blood, pancreas and liver.
The expression level of the K-RAS mRNA in the transplanted tumours was then detected, and the experimental results (
The tumour tissue proteins were extracted, and the expression level of the K-RAS protein in tumour tissues was detected using a western blotting experiment. It was found from the experimental results (see
Based on the K-RAS siRNA sequence designed in Example 1, up to 260 possible siRNA sequences for multiple sites of the K-RAS gene were further designed in this example, see Table 5 for details. 10 siRNA sequences with excellent stability and evident specific inhibitory effects were further screened from the siRNA sequences above for the expression verification. The sequence numbers of the 10 siRNAs were 3, 26, 41, 47, 52, 73, 88, 98, 101 and 106, respectively.
The expression levels of the K-RAS mRNA and the proteins were verified using the expression vector construction method in Example 1 and the verification method in Example 2, respectively.
The results above showed that the plasmids constructed using the screened 10 K-RAS siRNAs can significantly reduce the expression level of the K-RAS protein in the lung tumour tissues.
TABLE 5
K-RAS siRNA sense strand sequence
Sequence
number
siRNA sense strand
1
5′
GGCCAGUUAUAGCUUAUUA
3′
2
5′
GGUCCUAGUAGGAAAUAAA
3′
3
5′
GCAGCAGCAACAUUAAUAA
3′
4
5′
GGCAGACCCAGUAUGAAAU
3′
5
5′
GGUGUGCCAAGACAUUAAU
3′
6
5′
GGACUCUUCUUCCAUAUUA
3′
7
5′
GGCAAUGGAAACUAUUAUA
3′
8
5′
GCAGUUGAUUACUUCUUAU
3′
9
5′
GGACUUAGCAAGAAGUUAU
3′
10
5′
GCUCAGCACAAUCUGUAAA
3′
11
5′
CUCCUUUCCACUGCUAUUA
3′
12
5′
GCUGUGGAUAUUAUGUAAA
3′
13
5′
CUCAGCACAAUCUGUAAAU
3′
14
5′
GUUGGUGUGAAACAAAUUA
3′
15
5′
GGGCAUGUUAAGUUACAGU
3′
16
5′
GUGCCAAUUUCUUACUAGU
3′
17
5′
CACACUGCAUAGGAAUUUA
3′
18
5′
GCUCUUUCAUAGUAUAACU
3′
19
5′
CCUGGUAACAGUAAUACAU
3′
20
5′
GCUCAGGACUUAGCAAGAA
3′
21
5′
GACUAUGAGUGUGUAUUUA
3′
22
5′
GCCAUAGACACUAUAGUAU
3′
23
5′
GGCACUGGGUAUAUGGUAU
3′
24
5′
GACCCAGAGAUAACACGAU
3′
25
5′
GAGGAGUACAGUGCAAUGA
3′
26
5′
GGUAGCAGCAGCAACAUUA
3′
27
5′
CUCUGUGCCAGCUCUAUAA
3′
28
5′
GUGCUAGUGUGGUCUGUAA
3′
29
5′
CUGUACUACUCCUAAUUAU
3′
30
5′
CUAGUGUGGUCUGUAAUAU
3′
31
5′
GCAGACGUAUAUUGUAUCA
3′
32
5′
GGGCUAUAUUUACAUGCUA
3′
33
5′
GUGCUGUGAAGUGAUCUAA
3′
34
5′
CCUGUCUCUUGGAUAUUCU
3′
35
5′
GUGCUGUGGAUAUUAUGUA
3′
36
5′
GGAGGGCUUUCUUUGUGUA
3′
37
5′
CUAGGAAUGUUGGUCAUAU
3′
38
5′
CGUGUUUGCUUAAACUUAA
3′
39
5′
GCUGAUGCUUUGAACAUCU
3′
40
5′
GGUCUGUAAUAUCUUACUA
3′
41
5′
CCUUGACGAUACAGCUAAU
3′
42
5′
GUGGAUAUCUCCAUGAAGU
3′
43
5′
CACCAUUAUAGAGAACAAA
3′
44
5′
GCUUCCUGAUGAUGAUUCU
3′
45
5′
CAUCCCUGAUGAAUGUAAA
3′
46
5′
GAAGCAAGUAGUAAUUGAU
3′
47
5′
GGACGAAUAUGAUCCAACA
3′
48
5′
GUUCCCAAGUAGGCAUUCU
3′
49
5′
CCUGACCUCAAGUGAUUCA
3′
50
5′
GAACUGUACUACUCCUAAU
3′
51
5′
GUCCUUAGGUAGUGCUAGU
3′
52
5′
GGCUAUUUCAAGGUCAGAA
3′
53
5′
CCUGAUGAAUGUAAAGUUA
3′
54
5′
GUGUCAGACUGCUCUUUCA
3′
55
5′
CCGAAAUGGAUAUGGAAUA
3′
56
5′
GACUGCUCUUUCAUAGUAU
3′
57
5′
CAAGUCUGAUCCAUAUUUA
3′
58
5′
GAUGAGCAAAGAUGGUAAA
3′
59
5′
CAAGAGGUGAAGUUUAUAU
3′
60
5′
GGUAGGGUGUUAAGACUUA
3′
61
5′
CUAGGCAUCAUGUCCUAUA
3′
62
5′
GAGUGAAUGUUCCCAAGUA
3′
63
5′
CCUAGUAGGAAAUAAAUGU
3′
64
5′
GGAAGCAAGUAGUAAUUGA
3′
65
5′
GCUGUGGAUAUCUCCAUGA
3′
66
5′
CCAGAAAUCUUCAUGCAAU
3′
67
5′
GCCUGAACUAGUUCACAGA
3′
68
5′
CAGACGUAUAUUGUAUCAU
3′
69
5′
GUGUAUGUCAGAUAUUCAU
3′
70
5′
GGCUAGUUCUCUUAACACU
3′
71
5′
GAAGGUGACUUAGGUUCUA
3′
72
5′
GAACCUUUGAGCUUUCAUA
3′
73
5′
GCCUUGACGAUACAGCUAA
3′
74
5′
GAGUGCCAAUUUCUUACUA
3′
75
5′
CAGACAAGGAAACUUCUAU
3′
76
5′
CUUCGAUCAAGCUACUUUA
3′
77
5′
GCUGACAAAUCAAGAGCAU
3′
78
5′
GUCAUCUCAAACUCUUAGU
3′
79
5′
GUUGUCACCAUUGCACAAU
3′
80
5′
GAUGAUGCCUUCUAUACAU
3′
81
5′
CUGGUAUGAAUAGACAGAA
3′
82
5′
CACUGAGUCACAUCAGAAA
3′
83
5′
GUCAAGCUCAGCACAAUCU
3′
84
5′
GGACUCUGAAGAUGUACCU
3′
85
5′
GGGAUUAUUAUAGCAACCA
3′
86
5′
CUAGGAAGAAGGUGACUUA
3′
87
5′
CUGUGGAUAUCUCCAUGAA
3′
88
5′
GUGGACGAAUAUGAUCCAA
3′
89
5′
CAUGAGUUCUUGAAGAAUA
3′
90
5′
CUGAGUAGCUGGGAUUACA
3′
91
5′
GUGAACCUUUGAGCUUUCA
3′
92
5′
GACAAGGAAACUUCUAUGU
3′
93
5′
CAGUAAUACAUUCCAUUGU
3′
94
5′
CCUGGUAUGAAUAGACAGA
3′
95
5′
GAAUAUAGCAGACGUAUAU
3′
96
5′
CGAUCAAGCUACUUUAUGU
3′
97
5′
GGACAUCACUUACUAUCCA
3′
98
5′
GAAGGUAAUUGAUACACAA
3′
99
5′
CAAGGAAACUUCUAUGUAA
3′
100
5′
GAACCCAGCAGUUACCUUA
3′
101
5′
CAGCAGGCUAUUUCAAGGU
3′
102
5′
CUGAAUACCUAAGAUUUCU
3′
103
5′
GAUCAAGCUACUUUAUGUA
3′
104
5′
GCUCUAUUUAACUGAGUCA
3′
105
5′
CUAGAACAGUAGACACAAA
3′
106
5′
GAUACAGCUAAUUCAGAAU
3′
107
5′
GCAGGCUAUUUCAAGGUCA
3′
108
5′
CCUUAGGUAAUCUAUAACU
3′
109
5′
CCUAACCAUAAGAUUUACU
3′
110
5′
CCUACAGGAAGCAAGUAGU
3′
111
5′
GUGUUGAUGAUGCCUUCUA
3′
112
5′
GCUAUGUGAAACUACAGAU
3′
113
5′
GAAGUAAUGACUCCAUACA
3′
114
5′
CAUCAGAAAUGCCCUACAU
3′
115
5′
CUGCUGUGGAUAUCUCCAU
3′
116
5′
CUCGUUUCUACACAGAGAA
3′
117
5′
CACAUGAGUUCUUGAAGAA
3′
118
5′
GGUUUGGCUAGUUCUCUUA
3′
119
5′
GCUAUAUUUACAUGCUACU
3′
120
5′
CGAAUAUGAUCCAACAAUA
3′
121
5′
CCUCGUUUCUACACAGAGA
3′
122
5′
CCUUUCCACUGCUAUUAGU
3′
123
5′
GACUUAGGCAUUAACAUGU
3′
124
5′
CUCAUUUGUAUUCCAUUGA
3′
125
5′
GAAACUGAAUACCUAAGAU
3′
126
5′
GUGAGGUGAAAGUAUCACU
3′
127
5′
CAAAGACAAAGUGUGUAAU
3′
128
5′
GAGUCACACUGCAUAGGAA
3′
129
5′
GAUGGAGAAACCUGUCUCU
3′
130
5′
GAAAUGCCCUACAUCUUAU
3′
131
5′
GGAUACACUUAUUUGUCAA
3′
132
5′
CAGCAACAUUAAUAAUGGA
3′
133
5′
GAAUGUUGGUGUGAAACAA
3′
134
5′
CUGUUUAGGUAGGGUGUUA
3′
135
5′
GAAUGUUGGUCAUAUCAAA
3′
136
5′
GGAAGAAGGUGACUUAGGU
3′
137
5′
CACAGAGCUAACUGGGUUA
3′
138
5′
GAGAGUUUCACAGCAUGGA
3′
139
5′
GAUAGCUCAACAAGAUACA
3′
140
5′
GCAUAGGAAUUUAGAACCU
3′
141
5′
CACUGAAACUCUUCGAUCA
3′
142
5′
CCAUUUACAUAAGGAUACA
3′
143
5′
CAGUGACUAUGAGUGUGUA
3′
144
5′
GACUAGGGCAGUUUGGAUA
3′
145
5′
CUUUGUGUAUUUGCCAUAA
3′
146
5′
GAGUUAAGGACUCUGAAGA
3′
147
5′
GUCUCUUGGAUAUUCUCGA
3′
148
5′
GGAAGAAUAUAGCAGACGU
3′
149
5′
GACCUAGGAAUGUUGGUCA
3′
150
5′
GACUACUCCUGGUAACAGU
3′
151
5′
GCAGUUACCUUAAAGCUGA
3′
152
5′
GUUCUCUUAACACUGGUUA
3′
153
5′
GUCAAAGACAAAGUGUGUA
3′
154
5′
GCAAGUAGUAAUUGAUGGA
3′
155
5′
CACUGCUAUUAGUCAUGGU
3′
156
5′
CCGAAAGUUUCCAAUUCCA
3′
157
5′
GUGUUGAAGAGACCAAGGU
3′
158
5′
CAUCCAGUGUUGUCAUGCA
3′
159
5′
GACAUCACUUACUAUCCAU
3′
160
5′
GAAGAAUAUAGCAGACGUA
3′
161
5′
CAGUUUGGAUAGCUCAACA
3′
162
5′
GGAUUAUUAUAGCAACCAU
3′
163
5′
CCAAUUUCUUACUAGUACU
3′
164
5′
CCUAAUUAUUACAGCCUUA
3′
165
5′
CUGUACACAUUAAGGUGUA
3′
166
5′
CUGAAACAUUGAGGGAACA
3′
167
5′
CUAGGCUCUAUUUAACUGA
3′
168
5′
CAGUUACCUUAAAGCUGAA
3′
169
5′
CAAUGAGGGACCAGUACAU
3′
170
5′
CUAUAGUAUACCAGUGAAU
3′
171
5′
CCUUCUAGAACAGUAGACA
3′
172
5′
GAAACUGAAUAGCUGUCAU
3′
173
5′
GACUUACACAGUACCUCGU
3′
174
5′
CAGAAGUAAUGACUCCAUA
3′
175
5′
CAACUUGAGUCUUUGAAGA
3′
176
5′
GAAGAGACCAAGGUUGCAA
3′
177
5′
CUUGGAUAUUCUCGACACA
3′
178
5′
GAAAUGGAUAUGGAAUACU
3′
179
5′
GAACUCAUUUAUUCAGCAA
3′
180
5′
CGAUACAGCUAAUUCAGAA
3′
181
5′
GUCAUGCAUUGGUUAGUCA
3′
182
5′
GUCAGAAGUAAUGACUCCA
3′
183
5′
GAUUUCUGAAUUGCUAUGU
3′
184
5′
GAAUCUGACAGAUACCAUA
3′
185
5′
GAGAAUCUGACAGAUACCA
3′
186
5′
GAACUAGCAAUGCCUGUGA
3′
187
5′
GAAAUCUUCAUGCAAUGAA
3′
188
5′
CUUCUAUACAUUAGUUCGA
3′
189
5′
CAUCUCAUUUGUAUUCCAU
3′
190
5′
GAUAGCAUGAAUUCUGCAU
3′
191
5′
GCAUACUAGUACAAGUGGU
3′
192
5′
CUGAAGAUGUACCUAUGGU
3′
193
5′
CAAACCUGGUAUGAAUAGA
3′
194
5′
CAAGAUACAAUCUCACUCU
3′
195
5′
GAAUUGCUAUGUGAAACUA
3′
196
5′
GAUUUGACCUAAUCACUAA
3′
197
5′
CCAAUCCAUUAGCGACAGU
3′
198
5′
CAGAGAAAGAAAUGGCCAU
3′
199
5′
CUUGGCCUCAUAAACCUGU
3′
200
5′
CUAGUUCACAGACAAGGAA
3′
201
5′
CCAUUAGCGACAGUAGGAU
3′
202
5′
CCUACAUCUUAUUUCCUCA
3′
203
5′
CUAUGGUCCUAGUAGGAAA
3′
204
5′
CUGAAAGAAUUCCUUAGGU
3′
205
5′
CUAUGUUACACCAUCUUCA
3′
206
5′
GAAUUCCUUAGGUAAUCUA
3′
207
5′
CACUAUAGUAUACCAGUGA
3′
208
5′
CAUCAGCAAAGACAAGACA
3′
209
5′
CAAGAGGAGUACAGUGCAA
3′
210
5′
GGAAUACUUUAUAAGCCAU
3′
211
5′
CAUGAAUUCUGCAUUGAGA
3′
212
5′
GUUUCCAAUUCCACUGUCU
3′
213
5′
CAUGUCCUAUAGUUUGUCA
3′
214
5′
GUGAAAGUAUCACUGGACU
3′
215
5′
GAGUUUCACAGCAUGGACU
3′
216
5′
GUAACAUGUUUACCUGGAA
3′
217
5′
CUGAACUAGUUCACAGACA
3′
218
5′
CUCAAGAGAAUCUGACAGA
3′
219
5′
GUAACAGUAAUACAUUCCA
3′
220
5′
CAAUCCAUUAGCGACAGUA
3′
221
5′
GAAAGAUACUCACAUGAGU
3′
222
5′
CCAAAUGUGUAAUAUUCCA
3′
223
5′
GUUUGGGAUAAUGAUAGGU
3′
224
5′
CAACAAUAGAGGAUUCCUA
3′
225
5′
CAUGAACUGUACUACUCCU
3′
226
5′
GAAACAUUGAGGGAACACA
3′
227
5′
CUCUUGGAUAUUCUCGACA
3′
228
5′
GCAUUAACAUGUUUGUGGA
3′
229
5′
CUGAAUAUAAACUUGUGGU
3′
230
5′
GUAAAGGCGUGUUUGCUUA
3′
231
5′
CUUUGAACAUCUCUUUGCU
3′
232
5′
CCAUACUUCAGGAACUGCA
3′
233
5′
CUAUACAUUAGUUCGAGAA
3′
234
5′
CUUCUAGGCAUCAUGUCCU
3′
235
5′
GAAUACCUAAGAUUUCUGU
3′
236
5′
CAUACUAGUACAAGUGGUA
3′
237
5′
CAUAGGAAUUUAGAACCUA
3′
238
5′
GAAACUAUUAUAAGGCCAU
3′
239
5′
CUUAGCAAGAAGUUAUGGA
3′
240
5′
CUUCUGUGUUAAUACUGGA
3′
241
5′
CUUAAGGCAUACUAGUACA
3′
242
5′
CCUAUAGUUUGUCAUCCCU
3′
243
5′
CUUUGAGCUUUCAUAGAGA
3′
244
5′
CAAGUAGGCAUUCUAGGCU
3′
245
5′
CAAGAGACAUAAUCCCGGU
3′
246
5′
CAAUUCCACUGUCUUGUGU
3′
247
5′
GUUAUAGCUUAUUAGGUGU
3′
248
5′
GAUAUUCAUAUUGACCCAA
3′
249
5′
CAUAGAGAGUUUCACAGCA
3′
250
5′
GUAAUCUAUAACUAGGACU
3′
251
5′
GAACACAAAUUUAUGGGCU
3′
252
5′
GUUUAUAGGAGUAUGUGCU
3′
253
5′
CAUAAAGGGAUUUGACCUA
3′
254
5′
CAUAAGAUUUACUGCUGCU
3′
255
5′
CUUUGGUAUACGACCCAGA
3′
256
5′
GUAAACUGAAACAUGCACA
3′
257
5′
GGAAACUAUUAUAAGGCCA
3′
258
5′
CAAUUGUGAAUGUUGGUGU
3′
259
5′
CUAAGUGCCAGUAUUCCCA
3′
260
5′
CAUUUGAAGAUAUUCACCA
3′
261
5′
CUUAUUUCCUCAGGGCUCA
3′
262
5′
CAAAUAAACAGGUGCCUGA
3′
263
5′
GGUGACUUAGGUUCUAGAU
3′
3′
Two siRNAs (designated siRNA I and siRNA II) that inhibit the K-RAS expression in U.S. Pat. No. 8,008,474 B2 were selected.
siRNA I:
sense strand: 5′-CGAAUAUGAUCCAACAAUA-3′;
and
antisense strand: 5′-UAUUGUUGGAUCAUAUUCG-3′.
siRNA II:
sense strand: 5′-GAUGAUGCCUUCUAUACAU-3′;
and
antisense strand: 5′-AUGUAUAGAAGGCAUCAUG-3′.
Plasmid vectors were constructed in the same manner as in Example 1, designated siRNA I plasmid and siRNA II plasmid, respectively. The method in Example 2 was applied to the mouse Lewis lung cancer model, and the expression level of the K-RAS mRNA in each lung was then detected. The experimental results (
All the documents mentioned in the present invention are incorporatedly referred to, as well as each alone. In addition, it should be understood that after reading the teachings of the present invention described above, a skilled person in the art can make various changes or modifications of the invention, and these equivalent forms shall also fall into the scope of the present application as defined by the appended claims.
Chen, Xi, Zhang, Chenyu, Zeng, Ke, Liang, Hongwei, Ur-Rehman, Uzair
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 8008474, | Nov 14 2002 | Thermo Fisher Scientific Inc | siRNA targeting KRAS |
| 20130011922, | |||
| 20180223277, | |||
| WO2016177343, | |||
| WO2016177343, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| May 05 2017 | JIANGSU MICROMEDMARK BIOTECH CO., LTD. | (assignment on the face of the patent) | / | |||
| Nov 18 2018 | LIANG, HONGWEI | JIANGSU MICROMEDMARK BIOTECH CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 048723 | /0639 | |
| Nov 18 2018 | UR-REHMAN, UZAIR | JIANGSU MICROMEDMARK BIOTECH CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 048723 | /0639 | |
| Nov 19 2018 | CHEN, XI | JIANGSU MICROMEDMARK BIOTECH CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 048723 | /0639 | |
| Nov 20 2018 | ZHANG, CHENYU | JIANGSU MICROMEDMARK BIOTECH CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 048723 | /0639 | |
| Nov 20 2018 | ZENG, KE | JIANGSU MICROMEDMARK BIOTECH CO , LTD | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 048723 | /0639 |
| Date | Maintenance Fee Events |
| Nov 05 2018 | BIG: Entity status set to Undiscounted (note the period is included in the code). |
| Dec 06 2018 | SMAL: Entity status set to Small. |
| Date | Maintenance Schedule |
| Apr 20 2024 | 4 years fee payment window open |
| Oct 20 2024 | 6 months grace period start (w surcharge) |
| Apr 20 2025 | patent expiry (for year 4) |
| Apr 20 2027 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Apr 20 2028 | 8 years fee payment window open |
| Oct 20 2028 | 6 months grace period start (w surcharge) |
| Apr 20 2029 | patent expiry (for year 8) |
| Apr 20 2031 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Apr 20 2032 | 12 years fee payment window open |
| Oct 20 2032 | 6 months grace period start (w surcharge) |
| Apr 20 2033 | patent expiry (for year 12) |
| Apr 20 2035 | 2 years to revive unintentionally abandoned end. (for year 12) |